285 related articles for article (PubMed ID: 24830295)
1. Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Xiao F; Fofana I; Heydmann L; Barth H; Soulier E; Habersetzer F; Doffoël M; Bukh J; Patel AH; Zeisel MB; Baumert TF
PLoS Pathog; 2014 May; 10(5):e1004128. PubMed ID: 24830295
[TBL] [Abstract][Full Text] [Related]
2. A novel substitution in NS5A enhances the resistance of hepatitis C virus genotype 3 to daclatasvir.
Fernandes Campos GR; Ward J; Chen S; Bittar C; Vilela Rodrigues JP; Martinelli ALC; Souza FF; Pereira LRL; Rahal P; Harris M
J Gen Virol; 2021 Jan; 102(1):. PubMed ID: 33141008
[TBL] [Abstract][Full Text] [Related]
3. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
Guedj J; Neumann AU
J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C viral entry inhibitors prolong viral suppression by replication inhibitors in persistently-infected Huh7 cultures.
Bush CO; Greenstein AE; Delaney WE; Beran RK
PLoS One; 2013; 8(6):e65273. PubMed ID: 23755208
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Lindström I; Kjellin M; Palanisamy N; Bondeson K; Wesslén L; Lannergard A; Lennerstrand J
Infect Dis (Lond); 2015 Aug; 47(8):555-62. PubMed ID: 25851241
[TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
[TBL] [Abstract][Full Text] [Related]
8. Daclatasvir Prevents Hepatitis C Virus Infectivity by Blocking Transfer of the Viral Genome to Assembly Sites.
Boson B; Denolly S; Turlure F; Chamot C; Dreux M; Cosset FL
Gastroenterology; 2017 Mar; 152(4):895-907.e14. PubMed ID: 27932311
[TBL] [Abstract][Full Text] [Related]
9. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
10. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
11. Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice.
Vercauteren K; Brown RJ; Mesalam AA; Doerrbecker J; Bhuju S; Geffers R; Van Den Eede N; McClure CP; Troise F; Verhoye L; Baumert T; Farhoudi A; Cortese R; Ball JK; Leroux-Roels G; Pietschmann T; Nicosia A; Meuleman P
Gut; 2016 Dec; 65(12):2029-2034. PubMed ID: 26306759
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of HCV antiviral drug resistance.
Welsch C; Zeuzem S
Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585
[TBL] [Abstract][Full Text] [Related]
13. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
14. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.
Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M
Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115
[TBL] [Abstract][Full Text] [Related]
15. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins.
Li X; Li J; Feng Y; Cai H; Li YP; Peng T
Antiviral Res; 2020 May; 177():104734. PubMed ID: 32057770
[TBL] [Abstract][Full Text] [Related]
16. Multi-scale model for hepatitis C viral load kinetics under treatment with direct acting antivirals.
Clausznitzer D; Harnisch J; Kaderali L
Virus Res; 2016 Jun; 218():96-101. PubMed ID: 26409026
[TBL] [Abstract][Full Text] [Related]
17. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.
Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG
Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884
[TBL] [Abstract][Full Text] [Related]
18. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
Ramirez S; Bukh J
Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides.
Chukkapalli V; Berger KL; Kelly SM; Thomas M; Deiters A; Randall G
Virology; 2015 Feb; 476():168-179. PubMed ID: 25546252
[TBL] [Abstract][Full Text] [Related]
20. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
